EUVIMEDEUVIMED entdecken
Crossref

Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors

Yuki Nemoto, Hiroki Ishihara iD, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hiroaki Shimmura, Yasunobu Hashimoto, Tsunenori Kondo, Hiroshi Kobayashi, Toshio Takagi iD

International Journal of Urology · 2026

DOI: 10.1111/iju.70382 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yuki Nemoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tokiwakai Jyoban Hospital, Fukushima, Japan. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Nephrectomy, Immune Checkpoint Inhibitors. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Tokyo Women's Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Treatment outcomes for metastatic renal cell carcinoma (mRCC) have significantly improved with immune checkpoint inhibitors (ICIs); however, optimal treatment strategies remain incompletely defined. This study evaluated treatment outcomes in mRCC patients with intact primary renal tumors, focusing on the survival impact of cytoreductive nephrectomy (CN).

Methods

We retrospectively analyzed 104 consecutive mRCC patients (2019–2024) treated with immuno‐oncology combinations (IO+IO) or IO plus tyrosine kinase inhibitors (IO+TKI). Surgical timing was classified as upfront CN, deferred CN, or non‐CN. Landmark analyses at 6 and 12 months minimized immortal time bias. Multivariable analyses identified survival predictors.

Results

IO+IO patients were younger (63 vs. 68 years; p = 0.033) with higher progressive disease rates (31% vs. 2%), but similar objective response rates (50% vs. 47%) compared to IO+TKI. Of 104 patients, 25 underwent upfront CN, 25 deferred CN, and 54 non‐CN. Deferred CN independently predicted improved survival versus non‐CN in multivariable analysis (HR 0.17; 95% CI 0.05–0.57) and 6‐month landmark analysis (HR 0.22; 95% CI 0.06–0.83), but not at the 12‐month landmark, suggesting time‐varying effects.

Conclusions

IO+IO and IO+TKI demonstrated comparable efficacy with distinct profiles. Deferred CN may improve survival when performed within an optimal therapeutic window in selected patients, emphasizing the importance of treatment timing and response‐adapted selection in the ICI era.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal CellNephrectomyImmune Checkpoint InhibitorsCytoreduction Surgical ProceduresHumansFemaleRetrospective StudiesMaleAgedMiddle AgedTreatment OutcomeCombined Modality TherapyProtein Kinase Inhibitors

Stichwörter der Autor:innen

combination therapycytoreductive nephrectomyimmune checkpoint inhibitorkidney cancerrenal cancer

Substanzen

Immune Checkpoint InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Urology, Tokiwakai Jyoban Hospital, Fukushima, Japan.
  • Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.
  • Department of Urology, Saiseikai Kawaguchi General Hospital, Saitama, Japan.
  • Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
  • Department of Urology, Saiseikai Kazo Hospital, Saitama, Japan.

ORCID-Profile: Hiroki Ishihara, Toshio Takagi

Förderung

  • Tokyo Women's Medical University

Zitieren

APA

Nemoto, Y., Ishihara, H., Fukuda, H., Yoshida, K., Iizuka, J., Shimmura, H., Hashimoto, Y., Kondo, T., Kobayashi, H., & Takagi, T. (2026). Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors. International Journal of Urology. https://doi.org/10.1111/iju.70382

Vancouver

Nemoto Y, Ishihara H, Fukuda H, Yoshida K, Iizuka J, Shimmura H, et al. Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors. International Journal of Urology. 2026. doi:10.1111/iju.70382

BibTeX
@article{Nemoto2026,
  author = {Nemoto, Yuki and Ishihara, Hiroki and Fukuda, Hironori and Yoshida, Kazuhiko and Iizuka, Junpei and Shimmura, Hiroaki and Hashimoto, Yasunobu and Kondo, Tsunenori and Kobayashi, Hiroshi and Takagi, Toshio},
  title = {Impact of Cytoreductive Nephrectomy on Immune Checkpoint Inhibitor Therapy: Treatment Outcomes of Immune Inhibitors Combination Therapies for Metastatic Renal Cell Carcinoma With Primary Kidney Tumors},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70382}
}
Kostenlos starten →